A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome

Mooney, C.; Nagaiah, Govardhanan; Fu, Pingfu; Wasman, Jay; Cooney, Matthew M.; Savvides, Panos; Bokar, Joseph A.; Dowlati, Afshin; Wang, Ding; Agarwala, Sanjiv S.; Flick, S.; Hartman, Paul; Ortiz, Jose; Lavertu, Pierre; Remick, Scot C.

doi:10.1089/thy.2008.0321

Cited by 174 publications

(90 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The water-soluble phosphate prodrug CA4P, selected for further preclinical development, has drawn significant attention due to its potent and selective effect on tumor blood vessels, causing rapid vascular shutdown, leading to necrosis of the central tumor, an area that is often resistant to conventional anticancer treatments. The prodrug CA4P (forsbretabulin) is currently being evaluated, either alone or in combination with paclitaxel or carboplatin, in clinical studies for the treatment of patients with anaplastic thyroid carcinoma [6] or advanced cancer. [7,8] By binding to tubulin in tumor endothelial cells, VDAs such as CA4 cause rapid microtubule depolymerization.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Structure–Activity Relationships of Constrained Heterocyclic Analogues of Combretastatin A4

et al. 2011

View full text Add to dashboard Cite

A series of combretastatin A4 (CA4) analogues with a lactam or lactone ring fused to the trimethoxyphenyl or the B-phenyl moiety were synthesized in an efficient and stereoselective manner by using a domino Heck-Suzuki-Miyaura coupling reaction. The vascular-disrupting potential of these conformationally restricted CA4 analogues was assessed by various in vitro assays: inhibition of tubulin polymerization, modification of endothelial cell morphology, and disruption of endothelial cell cords. Compounds were also evaluated for their growth inhibitory effects against murine and human tumor cells. B-ring-constrained derivatives that contain an oxindole ring (in contrast to compounds with a benzofuranone ring) as well as analogues bearing a six-membered lactone core fused to the trimethoxyphenyl ring are endowed with significant biological activity. The most potent compound of this series (oxindole 9 b) is of particular interest, as it combines chemical stability and a biological activity profile characteristic of a vascular-disrupting agent.

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis and Structure–Activity Relationships of Constrained Heterocyclic Analogues of Combretastatin A4

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Median duration of stable disease was 12.3 months (range 4.4-37.9). Low-baseline soluble intracellular adhesion molecule-1 (sICAM) appeared to predict better event-free survival [45]. In a Phase 2/3 trial, fosbretabulin, paclitaxel, and carboplatin combination was compared to carboplatin and paclitaxel only in 80 patients with ATC.…”

Section: Emerging Therapiesmentioning

confidence: 99%

Rapid Recurrence of Anaplastic Carcinoma: Advocacy towards Non-Surgery

Habra¹

2017

EMIJ

View full text Add to dashboard Cite

DiscussionThe majority of anaplastic cancers are revealed by the rapid transformation of an old goitre: increase in volume, pain, dysphonia, dyspnea by tracheal compression and dysphagia thereafter. The nodal invasions, the repercussion on the general state, immediately sign the gravity of the situation. The cervical ultrasound is not specific but allows suspecting a malignant AbstractAnaplastic carcinoma of the thyroid (ATC) is a rare but aggressive tumor, its prognosis is dark. Most patients diagnosed with this disease are 65 years of age or older, treatment is based on the combined action of radiotherapy, chemotherapy and surgical removal when possible. We report a case of anaplastic carcinoma of the thyroid which has been thundering in postoperative surgery after total thyroidectomy, this case highlights the ineffectiveness of surgery in the reduction of tumor mass. Surely contribute to a historical recurrence and aggravate the prognosis. We will study through a review of the literature the clinical aspects and discuss the therapeutic modalities of this cancer.Keywords: Anaplastic thyroid carcinoma; Therapeutic modalities

show abstract

“…Of all the aforementioned, sorafenib, 30---32 axitinib, 33 gefitinib, 34 imatinib, 35 and the antimicrotubule fosbretabulin and combretastatin A4 phosphate agents 36 have been studied in phase II clinical trials with a small number of patients with promising results and a 33---75% rate of disease control. There are several studies underway with different drugs in monotherapy or associated with chemotherapy.…”

Section: What Systemic Therapies Should Be Considered For Metastatic mentioning

confidence: 99%

Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma

Sanchis

Jiménez‐Fonseca

Sandi

et al. 2015

Endocrinología y Nutrición

View full text Add to dashboard Cite

A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome

Cited by 174 publications

References 39 publications

Synthesis and Structure–Activity Relationships of Constrained Heterocyclic Analogues of Combretastatin A4

Synthesis and Structure–Activity Relationships of Constrained Heterocyclic Analogues of Combretastatin A4

Rapid Recurrence of Anaplastic Carcinoma: Advocacy towards Non-Surgery

Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma

Contact Info

Product

Resources

About